The immune system seems to prevent an experimental vaccine induced antibodies that protect against HIV infection, but there may be ways to overcome this obstacle, according to research conducted by the Duke Institute for Human Vaccines.
Using rodent models and monkeys, researchers demonstrated that they could identify the obstacles to could lead to wideneutralizing antibodiesWhich are considered imperative to the success of protection against infection.
Editor's Note: Antibodies broadly neutralizing antibody is one that maintains a cell of an antigen or infectious organism to inhibit or neutralize any biological effect. An example of a neutralizing antibody is diphtheria antitoxin, which can neutralize the biological effects of diphtheria toxin. This text uses the Wikipedia material, licensed under CC-BY-SA,
They are looking for "alternative routes" for antibodies that address the protective antibodies neutralizing capacity and setting the path for potential strategies to circumvent theImmune systemResponse to activate the desired protection from a potential vaccine.
"This is the first demonstration of the extraordinary ability of the immune system to circumvent this process to thwart the development of broadly neutralizing antibodies in mice and monkeys, and is very useful for us to begin to predict how the human immune system will respond," said Barton F. Haynes, MD, director of the Duke Institute for Human Vaccines.
Haynes is senior author of a study published in April 27, 2016, the magazineScience Translational Medicine.
Even in mice Recombinant "specially designed" (editor quotes) to receive broadly neutralizing antibodies when vaccinated with a vaccine against HIV, the experimental study of the immune system interrupts the process. Haynes that said reaction is a result of the virus's ability to simulate the host, causing the immune system fails to execute the command, and an attack, and scale in a process known asimmune tolerance. When the experimental vaccine was introduced into mice, the antibody comado process was reactivated but not expanded and developed as needed.
In monkeys, experimental vaccineIt led to a new type of antibodies and demonstrated an alternative approach to neutralizing antibodies.
"What we hope is that the experimental vaccine, which is designed for the human immune system will accomplish something much greater in humans than in apes," said Haynes. "We are working on getting ways around the final hurdle than limit Neutralizing antibodies Widely.
We want to, but this is more than what we had done so far. "
4 May 2016 by Sarah Avery
Translated by Claudio Souza, the original Researchers find alternative pathways to HIV antibodies. Reviewed by Mara Macedo
More information:R. Zhang et al. Home immune tolerance gp41 controlled HIV neutralizing B cell lines,Science Translational Medicine(2016).DOI: 10.1126 / scitranslmed.aaf0618
Official reference:Science Translational Medicine
Provided by:Duke University